Liquid Biopsies: Lowering the Defenses of Resistant Lung Cancer

14/12/2016 - 4 minutes

In response to new treatments, cancer came back stronger and more resistant than ever. Medicine’s counterattack will be more effective with a clear target.

How do you solve a problem like drug resistance in cancer research? There’s no clear-cut answer yet, not least because the disease can vary so widely. But there has been some exciting research working around drug resistance e.g. lung cancer therapies.

As an example, EGFR is overexpressed in a number of cancers, including squamous cell lung cancer. The first generation of drugs, tyrosine kinase inhibitors (TKI’s), worked by checking its up-regulation. However, tumors quickly developed resistance to these treatments, presenting a new challenge to medical researchers.

It was discovered that a mutation, T790M, is present in over 50% of TKI-resistant tumors: consequently, it became the target of second- and third-generation lung cancer therapies. But this leaves almost half of drug-resistant lung cancers without explanation or a target, so there is a nearly 50% chance that the second line of treatment will be ineffective.

romaset

A biopsy of the tumor is usually the primary means of analysis,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member